🔬‼️ When brain metastases appear could be a key factor in the survival of patients with advanced
#breastcancer 🧠
🧪 A new subgroup analysis from the
@GEICAM RegistEM study, recently published in the journal Therapeutic Advances in Medical Oncology, provides real-world evidence on how central nervous system involvement (
#CNS) impacts clinical outcomes.
📊 From the study, which analyzed 1,947 women with advanced breast cancer, it was found that 18% developed brain metastases. Of these, 25% already had CNS involvement at the time of diagnosis, with a median
#survival of 26 months, compared to only 9 months in those who developed metastases during the disease.
🧬 Relevant differences were also observed according to subtype.
#HER2 and triple-negative tumors were the most likely to develop brain metastases early. In particular, patients with
#triplenegative breast cancer showed the worst survival, with a median of just 6 months after the diagnosis of brain metastases.
💡 These results reinforce the importance of having therapies with intracranial activity, especially in higher-risk subgroups, and highlight the need to advance strategies for the prevention and management of
#metastases in the CNS.
💜 Thank you to all the authors, researchers, and collaborating centre teams for this important work!
📝 The full press release is available below for more information:
➡️
geicam.org/wp-content/upload…